皇家制药版税 RPRX
$67.30 −$0.27 (-0.40%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $68.80 +2.23%
开盘$66.52
昨收$67.57
当日区间$66.52 – $68.15
成交量4.84M
市值$29.97B
市盈率（TTM）44.0
股息率1.37%
RPRX 相关新闻
匹配 Royalty Pharma 或代码 RPRX 的头条新闻，按最新排序。
- Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $70
- TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $68 正面
- UBS Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $66
- Royalty Pharma(RPRX.US) Officer Sells US$5.85 Million in Common Stock
- BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Announces Target Price $63
- Form 144 | Royalty Pharma(RPRX.US) Officer Proposes to Sell 5.85 Million in Common Stocks
- Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $66 正面
- Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $65
- Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $65 正面
- Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $70 正面
- UBS Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $66 正面
- J.P. Morgan Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $62 正面
- Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $66
- TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $65 正面
- BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating
暂无评论——快来第一个聊聊 RPRX。
登录后参与讨论。